Paion AG
PA8
Ранг среди акций
#35737
Paion AG is a specialized pharmaceutical firm engaged in the global development... Paion AG is a specialized pharmaceutical firm engaged in the global development and commercialization of medicines for hospital settings, specifically addressing needs in sedation, anesthesia, and critical care. Its primary compound, Remimazolam, is an ultra-short-acting intravenous benzodiazepine designed as a sedative/anesthetic, currently progressing through clinical trials for applications in procedural sedation, general anesthesia, and intensive care unit sedation. The company's pipeline also includes Angiotensin II, a vasoconstrictor for treating severe low blood pressure in adults experiencing septic or other forms of distributive shock, and Eravacycline, a new fluorocycline antibiotic targeting complex intra-abdominal infections in adults. Paion AG collaborates with various partners through licensing and strategic agreements, including Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Established in 2000, Paion AG operates from Aachen, Germany.
Цена акции
$0.42701586
Последняя синхронизация: 2023-11-01
Рыночная капитализация
$3.21M
Изменение (1 день)
16.99%
Изменение (1 год)
3,295.00%
Страна
DE
Торговля Paion AG (PA8)
Категория
Healthcare
История цены акций Paion AG (PA8)
Наивысшая цена закрытия: $0.01 2025-09-01
Наименьшая цена закрытия: $7.36 2023-03-01
Наименьшая цена закрытия: $7.36 2023-03-01
История цены акций Paion AG с 2023 по 2026
Годовая динамика цены акций
| Год | Результативность |
|---|---|
| 2025 | -20.23% |
| 2024 | -93.11% |
| 2023 | 0.00% |
Цена акций похожих компаний или конкурентов
| Компания | Цена акций | Изменение 1г% | Страна |
|---|---|---|---|
| $171.67 | - |
DE
|
|
| $163.40 | 22.20% |
DE
|
|
| $40.45 | 43.11% |
JP
|
|
| $225.72 | 31.81% |
CH
|
|
| $18.43 | -4.03% |
IN
|
